英和和英

出典:『Wikipedia』 (2011/05/15 12:48 UTC 版)

英語による解説

引用

PUGNAc is a 1,5-hydroximolactone, acting as an inhibitor of a variety of N-acetylhexosaminidases. It was long thought that increased levels of O-GlcNAc in human cells lead to Type II diabetes. O-GlcNAc levels were artificially raised with PUGNAc, which inhibits O-GlcNAcase, a beta-exo-N-acetylhexosaminidase which cleaves beta-O-linked-N-acetylglucosamine residues from glycoproteins. As a result of this inhibition, a type II diabetic phenotype was observed. It was unknown however, whether it was the increased O-GlcNAc levels or inhibition of another N-acetylhexosaminidase within the cell which was generating this phenotype. Recent studies have shown, using a selective O-GlcNAcase inhibitor, that there is no corellation between increased O-GlcNAc levels on glycoproteins and Type II diabetes.